GHRP-2 vs GHRP-6
Verdict: GHRP-2 releases somewhat more GH per microgram; GHRP-6 triggers dramatically more hunger through stronger ghrelin mimicry. That hunger is the real decision point: for someone force-feeding a bulk, GHRP-6's appetite surge is a feature; for everyone else it's the reason these are legacy compounds. Both nudge cortisol and prolactin at higher doses — the flaw that ipamorelin was designed to eliminate. In 2026, the honest answer to 'which one?' is usually 'ipamorelin instead,' unless the hunger effect itself is what you're after.
Side by side
| GHRP-2 | GHRP-6 | |
|---|---|---|
| Typical dose | 100 mcg–300 mcg | 100 mcg–300 mcg |
| Frequency | 1–3x daily | 1–3x daily |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 5 mg | 5 mg |
| Typical mix | 5 mg + 2 ml water | 5 mg + 2 ml water |
| Units for typical dose | 8 units (200 mcg) | 8 units (200 mcg) |
Where they differ pharmacologically
Both are first/second-generation ghrelin-receptor agonists dosed 100–300 mcg up to three times daily. GHRP-2 is modestly more potent for GH release and slightly cleaner on side effects; GHRP-6 binds in a way that produces the strongest appetite stimulation of any peptide in common circulation — users report genuine, urgent hunger within minutes of injection.
The cortisol/prolactin caveat
At standard doses the elevation is mild and transient; at aggressive doses (300 mcg+ multiple times daily) both compounds can push cortisol and prolactin enough to matter over a long cycle. This is the main reason protocols moved to ipamorelin, which is functionally silent on both axes.
Cost is their surviving argument
GHRP-2 and GHRP-6 are old, off-patent and cheap — often half the price of ipamorelin per milligram. For a budget-constrained protocol where mild cortisol elevation is acceptable, they still do the job they always did.
Can you stack them?
Same slot as ipamorelin: pair with a GHRH analog (CJC-1295 no DAC or sermorelin) for the synergistic pulse. Never stack two secretagogues together — they compete for the same receptor with no added benefit.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.